This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/2/310    most recent 01.ATV.0000254147.89321.cfv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ivanciu, L. Articles by Lupu, C. Search for Related Content PubMed PubMed Citation Articles by Ivanciu, L. Articles by Lupu, C. Related Collections Fibrinogen/fibrin Gene therapy Other Vascular biology Angiogenesis Gene regulation

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:310.)
© 2007 American Heart Association, Inc.

Vascular Biology

Adenovirus-Mediated Expression of Tissue Factor Pathway Inhibitor-2 Inhibits Endothelial Cell Migration and Angiogenesis

Lacramioara Ivanciu; Robert D. Gerard; Haiwang Tang; Florea Lupu; Cristina Lupu

From the Cardiovascular Biology Research Program (L.I., H.T., F.L., C.L.), Oklahoma Medical Research Foundation, Oklahoma City; the Department of Internal Medicine (R.D.G.), University of Texas Southwestern Medical Center, Dallas; and the Department of Pathology (F.L.), Oklahoma University Health Sciences Center, Oklahoma City.

Correspondence to Cristina Lupu, PhD, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104. E-mail cristina-lupu{at}omrf.ouhsc.edu

Objective— Extracellular matrix (ECM) remodeling during angiogenesis is accomplished through plasmin-dependent pericellular proteolysis and through the action of matrix metalloproteinases (MMPs). Because tissue factor pathway inhibitor-2 (TFPI-2), a Kunitz-type protease inhibitor with prominent ECM localization, inhibits plasmin and MMPs activity, we investigated the role of TFPI-2 in endothelial cell (EC) migration and angiogenesis.

Methods and Results— Real-time polymerase chain reaction and immunostaining showed that the expression of TFPI-2 mRNA and protein was upregulated in migrating ECs. The effect of TFPI-2 on angiogenesis was studied in mouse models of Matrigel and polyvinylalcohol sponge implants by overexpressing TFPI-2 through infection with a replication-deficient adenovirus (AdTFPI-2). Using (immuno)fluorescence and confocal microscopy we observed that TFPI-2 reduced neovascularization and promoted ECM deposition. Lateral cell migration and capillary tube formation in vitro also were impaired by TFPI-2, a process reversed by anti–TFPI-2 antibodies. Increased apoptosis occurred both in AdTFPI-2–treated ECs and in the mouse implants. Zymography and assays in the absence of plasminogen confirmed plasmin inhibition as a main mechanism through which TFPI-2 inhibits EC migration.

Conclusions— Our data suggest that TFPI-2 may be an important regulator of aberrant angiogenesis associated with tumor growth/metastasis, cardiovascular diseases, chronic inflammation, or diabetes.

This study shows that overexpression of TFPI-2 is an effective strategy to suppress angiogenesis. The mechanism apparently involves inhibition by TFPI-2 of plasmin and/or MMPs, thus reducing cell migration, promoting extracellular matrix deposition, and inhibiting neovascularization. The present data raise the possibility that TFPI-2 is a negative regulator of physiological angiogenesis.

Key Words: TFPI-2 • angiogenesis • endothelial cell • adenovirus gene delivery • mouse model